Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II HSK31858 in chronic airway inflammatory disease with mucus hypersecretion
ChiCTR2500105501Phase 2Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HSK31858 in bronchiectasis, chronic obstructive pulmonary disease (COPD) and asthma (3 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Change in 24-hour sputum volume after 12 weeks of treatment compared to baseline. Started Jul 2025; status: recruiting.
02
Drugs
HSK31858
03
Conditions
bronchiectasischronic obstructive pulmonary disease (COPD)asthma
Beyond the preview
Go deeper on ChiCTR2500105501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105501.